Founded in 2013, Dr. Zhu’s Lab is dedicated to advancing biomedical research, educating students, and fostering career opportunities for young scholars. We are a multidisciplinary team working together to address important scientific questions and innovate key platform technologies.
Combine single-cell microfluidics and library display with deep sequencing to discover functional antibodies.
Self-assembling nanoparticle + Stabilized envelope trimer = Prophylactic HIV vaccine
This animation depicts how one of our leading HIV-1 vaccine candidates is designed. Dihydrolipoyl acetyltransferase (E2p) from Bacillus stearothermophilus is a protein that can automatically assemble into a 60-meric nanoparticle with a diameter of 23.2 nm. After an HIV-1 envelope glycoprotein (Env) has been stabilized by our “uncleaved, prefusion-optimized (UFO)” design, it can be displayed on the E2p surface through gene fusion. The outcome is a nanoparticle vaccine of 40-60 nm in size with 20 native-like viral spikes on the surface poised for immune recognition.
September 21, 2020 - Scripps Research, La Jolla, CA In a new study that demonstrates the promise of a novel vaccine approach for COVID-19, Scripps Research scientist Jiang Zhu, PhD, showed that his protein nanoparticle [...]
April 15, 2020 - Scripps Research, La Jolla, CA A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a study from scientists at Scripps Research. [...]
March 25, 2019 - NIH Division of AIDS (DAIDS), ABL Inc, Ufovax Inc and Dr. Zhu (on behalf of Scripps Research) held a kickoff meeting to start the cGMP process development for the HIV-1 nanoparticle [...]